Quantinno Capital Management LP Sells 8,774 Shares of Enovis Co. (NYSE:ENOV)

Quantinno Capital Management LP trimmed its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 30.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,030 shares of the company's stock after selling 8,774 shares during the period. Quantinno Capital Management LP's holdings in Enovis were worth $879,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ENOV. Vanguard Group Inc. grew its position in shares of Enovis by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after buying an additional 75,348 shares during the period. DAVENPORT & Co LLC boosted its stake in Enovis by 6.0% during the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock worth $121,181,000 after acquiring an additional 157,216 shares during the last quarter. Royce & Associates LP grew its holdings in Enovis by 2.8% during the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after purchasing an additional 66,891 shares during the period. River Road Asset Management LLC grew its holdings in Enovis by 3.8% during the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after purchasing an additional 45,762 shares during the period. Finally, Boston Partners increased its stake in Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company's stock valued at $46,034,000 after purchasing an additional 223,816 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 1.0%

Shares of ENOV traded down $0.32 on Thursday, hitting $32.25. The company's stock had a trading volume of 126,450 shares, compared to its average volume of 789,690. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $51.00. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm's fifty day moving average price is $34.32 and its 200-day moving average price is $40.80. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -14.71 and a beta of 1.79.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. During the same quarter in the prior year, the firm posted $0.50 EPS. The business's revenue was up 8.2% on a year-over-year basis. On average, equities research analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of recent analyst reports. JMP Securities reduced their price target on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group reduced their target price on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Needham & Company LLC decreased their target price on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.